Cross-vaccination with an mRNA vaccine offers a better immune response against the coronavirus than double Astrazeneca vaccination, according to one study.
Munich – Anyone who is given one of the mRNA vaccines as secondary protection after vaccination with the corona vaccine from Astrazeneca is better protected according to a joint study. This is what the Munich Helmholtz Center and several universities in Bavaria and North Rhine-Westphalia found out in a study on the double Astrazeneca vaccination. The study found that the antibody response against the coronavirus in so-called cross-vaccination is “much more pronounced”.
For the study, the researchers from the Helmholtz Center, the Technical University of Munich and the university clinics in Erlangen and Cologne examined blood samples from 500 test subjects who had received cross-vaccination with Astrazeneca and the mRNA vaccines from Biontech / Pfizer or Moderna. The scientists were able to analyze the blood samples for their immune reaction. After cross-vaccination, they were consistently at least as good as when they were vaccinated twice with the Biontech vaccine. The results were published in a medical journal from the British group “The Lancet”.
Effective cross-vaccination with Astrazeneca and mRNA: problems for travelers
The researchers see the combination vaccination as a further building block to generally improve the effectiveness of the Covid-19 vaccination. This is reported by the AFP news agency. In addition, cross-vaccination can be used effectively in the event of individual intolerance or supply bottlenecks. For the final confirmation of the study results, however, further studies, also on the safety and clinical effectiveness of the combination vaccinations, are required.
The Standing Vaccination Commission has already recommended cross-vaccination with the Astrazeneca vaccination for under 60s. A problem with this variant, however, is that numerous countries have already announced that they will not recognize cross-vaccination for the entry of tourists. However, the countries of the European Union have agreed to recognize cross-vaccination as effective, provided that it has been carried out with vaccines approved in the EU. Denmark, where over 150,000 people have received a cross-vaccination, is currently planning to re-vaccinate with a third dose to prevent travel disadvantages for affected citizens. (ska / AFP)
List of rubric lists: © Sven Hoppe / dpa
